Retatrutide and Tirzepatide from ₱750 a vial in 25, 50 and 100 packs. Split it with friends or resell it under your own label.From ₱750 a vial: 25, 50 and 100 packs for group buys and resellers. See bulk prices →

2026 Decision Hub

Weight loss peptides in the Philippines

Retatrutide, tirzepatide, semaglutide and cagrilintide compared on what their human trials found, their US FDA status and Philippine pharmacy availability, with the side effects covered on each compound page.

Philippines Peptides editorial deskUpdated 6 min read

Video guide: GLP-1 Medicines in the Philippines, Explained (2:12)
Video transcript

New to GLP-1s in the Philippines? Here is what they are, what is registered, and the three ways to get them. GLP-1 is a hormone released after you eat. These medicines mimic it: more fullness, more insulin, slower digestion. Semaglutide acts on one receptor, tirzepatide on two, and retatrutide on three. Retatrutide is still investigational. In phase 3 trials, top-arm mean weight loss was 14.9% in STEP 1, 20.9% in SURMOUNT-1, and 28.3% in TRIUMPH-1. Ozempic, Wegovy, Mounjaro and Rybelsus are registered with FDA Philippines as prescription medicines. Prescribing belongs with a licensed Philippine physician. Route one, a pharmacy. At Watsons, an Ozempic 1 mg pen is ₱9,280. Mounjaro pens reach ₱29,900. Route two, telehealth, after a doctor's review. GoRocky lists from ₱3,990 a month. &you, ₱599 a month after a free first month, plus medication. Route three, research vials. Not the same product: a pen is a registered prescription medicine. A research vial is not approved for human use and is sold for research only. Our partner and supplier, Primara Labs, lists 15 mg vials: semaglutide, ₱1,990. Tirzepatide, ₱1,890. Retatrutide, [₱3,390 for the 20 mg vial]. Per mg, the Ozempic pen is about ₱2,320. The semaglutide research vial works out at ₱133 per mg, or ₱81 in a 10 pack. Not the same product. Every order includes bacteriostatic water, syringes and alcohol pads. Same day in Metro Manila before noon, J&T nationwide, and a 60-day money-back guarantee. Read the full GLP-1 guide on Philippines Peptides, then see the research vials at Primara Labs and order on WhatsApp. [Figures in square brackets corrected on 3 November 2026 from Primara's current catalogue: the narration gives the price of the 15 mg retatrutide vial, retired on 12 October 2026.]

TRIUMPH-1 mean weight lossPhase 3, 12 mg arm, 80 wk
28.3%
Compounds
04

GLP-1 head-to-head

Comparison table

GLP-1 / Multi-agonist peptides: PH 2026
CompoundMean weight loss, largest armFDAPH Pharmacy
Retatrutide28.3% on 12 mg, TRIUMPH-1 (phase 3, 80 wk)Phase 3Not available
Tirzepatide20.9% on 15 mg, SURMOUNT-1 (phase 3, 72 wk)FDARegistered as Mounjaro, prescription only
Semaglutide14.9% on 2.4 mg, STEP 1 (phase 3, 68 wk)FDARegistered as Ozempic and Wegovy, prescription only
CagrilintideNo trial figure on filePhase 3Not available

Figures are mean body-weight change in each compound's pivotal trial, read from the synced trials dataset. Side effects from the same trials are on each compound page.

How the three trial programmes compare

Retatrutide is a triple agonist (GLP-1, GIP and glucagon receptors) developed by Eli Lilly. It is investigational and approved nowhere. In TRIUMPH-1, an 80-week phase 3 trial of 2,339 adults with obesity, or overweight with at least one weight-related condition, without diabetes, body weight fell by 19%, 25.9% and 28.3% on the 4 mg, 9 mg and 12 mg arms, against 2.2% on placebo. Source The retatrutide guide lists its side effects from the same trials and its regulatory status, and the retatrutide Philippines 2026 guide covers the Philippine picture.

Semaglutide is a GLP-1 receptor agonist developed by Novo Nordisk, the active ingredient in Ozempic (approved by the US FDA for type 2 diabetes in 2017) and Wegovy (approved for weight management in 2021). In STEP 1, a 68-week phase 3 trial of 1,961 adults with BMI of 30 or greater (27 or greater with at least one weight-related coexisting condition), without diabetes, body weight fell by 14.9% on the 2.4 mg arm, against 2.4% on placebo. Source Start with the semaglutide Philippines 2026 guide.

Tirzepatide is a dual agonist (GLP-1 and GIP receptors) developed by Eli Lilly, the active ingredient in Mounjaro and Zepbound. In SURMOUNT-1, a 72-week phase 3 trial of 2,539 adults with BMI of 30 or more, or 27 or more with at least one weight-related complication, excluding diabetes, body weight fell by 15%, 19.5% and 20.9% on the 5 mg, 10 mg and 15 mg arms, against 3.1% on placebo. Source Read the tirzepatide Philippines 2026 guide.

These trials enrolled different populations over different lengths of time, so the figures are not a head-to-head comparison. Each compound page places the adverse events from the same trials next to the outcomes.

The four options explained

Triple-agonist

Retatrutide

Retatrutide is a triple-agonist peptide that activates GLP-1, GIP, and glucagon receptors. In TRIUMPH-1, a phase 3 trial, the 12 mg arm lost 28.3% of body weight on average at 80 weeks. In the Philippines, retatrutide isn't available at any pharmacy or hospital. The retatrutide Philippines 2026 guide covers COA red flags and legal status.

Dual-agonist

Tirzepatide

Tirzepatide is a dual-agonist peptide that activates both GLP-1 and GIP receptors. In SURMOUNT-1, a phase 3 trial, the 15 mg arm lost 20.9% of body weight on average at 72 weeks. Mounjaro registration and dated pharmacy prices are on the Mounjaro page. See the tirzepatide Philippines 2026 guide or the focused tirzepatide weight loss page.

GLP-1 single-agonist

Semaglutide

Semaglutide is a GLP-1 receptor agonist, FDA-approved as Ozempic (diabetes) and Wegovy (obesity). In STEP 1, a phase 3 trial, the 2.4 mg arm lost 14.9% of body weight on average at 68 weeks. See the semaglutide Philippines 2026 guide or the focused semaglutide weight loss page.

Amylin analogue

Cagrilintide

Cagrilintide is an amylin analogue that works through a different mechanism than GLP-1 agonists. Amylin slows gastric emptying and signals satiety via different brain pathways than GLP-1. Novo Nordisk is testing cagrilintide combined with semaglutide in phase 3. The trials dataset this site draws on holds no cagrilintide result, so this page states no figure for it.

Branded medicines and research-grade peptides

Ozempic, Wegovy and Mounjaro are prescription medicines. Registration numbers and dated pharmacy prices are on the GLP-1 price tracker.

Prescription only; prescribing belongs with a licensed Philippine physician. Trials and side effects: the tirzepatide guide. The law: regulation hub.

Research-grade peptides are a separate category: research materials, not pharmacy products, and not a substitute for a prescribed medicine. The supplier checklist sets out what to ask a seller before paying, and the buying peptides in the Philippines guide covers the rules on personal import.

A proper COA comes from a third-party lab independent of the seller, shows HPLC purity testing with a clear chromatogram, lists actual peptide content in milligrams, and includes the specific batch number that matches your vial. The COA verification guide explains how to read HPLC chromatograms and spot fake certificates.

Before buying anything

Work through the supplier checklist and the COA guide, and read the compound page for what its trials found and the side effects they reported. Anything you intend to use belongs in a conversation with a licensed Philippine physician first.

Updated